SCHEDULE: RA Capital Increases Stake in Solid Biosciences

RA Capital Management has increased its beneficial ownership in Solid Biosciences Inc. through recent open market and ATM offering purchases.

Summary

• RA Capital Management, L.P. and its affiliates increased their stake in Solid Biosciences Inc. to 12,036,126 shares.
• The total beneficial ownership represents approximately 11.9% of the company's outstanding common stock.
• Purchases included 338,100 shares via open market transactions at a weighted-average price of $8.30 per share on June 18, 2026.
• An additional 2,358,048 shares were acquired at $8.20 per share through an at-the-market (ATM) offering on June 22, 2026.
• The reporting persons hold pre-funded warrants for 8,178,412 shares, currently restricted by a 9.99% beneficial ownership blocker.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as it reflects strong institutional commitment and successful capital raising, though it acknowledges the dilutive impact of the ATM offering.

Positives

• Significant increase in institutional investment from a major healthcare-focused fund.
• Demonstrates strong confidence from a long-term investor in the company's strategic direction.
• Successful execution of an at-the-market offering, providing capital to the issuer.

Negatives

• The acquisition of shares through an ATM offering results in dilution for existing shareholders.

Risks

• The 9.99% beneficial ownership blocker on pre-funded warrants limits the immediate conversion of these instruments into common stock.
• Reliance on market conditions for future capital raising activities.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but indicates continued financial support from a major institutional shareholder.

Industry Context

StockSavvy.ai notes that increased institutional accumulation in clinical-stage biotech firms often signals confidence in upcoming trial data or pipeline milestones, despite the dilutive nature of ATM offerings.

Comparison to Industry Standards

• The 11.9% stake is consistent with RA Capital's strategy of maintaining significant influence in its core biotech holdings.
• The use of ATM offerings is a standard capital-raising mechanism for mid-cap biotech companies to extend cash runways.

Stakeholder Impact

• Shareholders: Potential dilution from the ATM offering.
• Company: Strengthened balance sheet through capital infusion.

Next Steps

• Continued monitoring of RA Capital's holdings for further changes in beneficial ownership.
• Potential future exercise of pre-funded warrants if the ownership blocker is addressed.

Key Dates

Recommendation

The stock is likely to see volatility due to the institutional buying and the dilutive effect of the ATM offering; investors should hold until further clinical or operational catalysts are announced.

Keywords

Solid Biosciences, RA Capital, Schedule 13D, Biotech, Institutional Investor, Equity Offering